Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

NLTX | Neoleukin Therapeutics Inc

Index- P/E- EPS (ttm)-0.85 Insider Own20.78% Shs Outstand42.65M Perf Week-9.35%
Market Cap153.63M Forward P/E- EPS next Y- Insider Trans33.21% Shs Float34.87M Perf Month-3.83%
Income-42.81M PEG- EPS next Q-0.15 Inst Own44.47% Short Float / Ratio0.07% / 0.40 Perf Quarter-11.08%
Sales0.00M P/S- EPS this Y69.23% Inst Trans-12.19% Short Interest0.02M Perf Half Y10.11%
Book/sh1.81 P/B1.93 EPS next Y- ROA-37.06% Target Price7.50 Perf Year-5.68%
Cash/sh1.86 P/C1.87 EPS next 5Y- ROE-43.62% 52W Range1.88 - 4.70 Perf YTD37.13%
Dividend- P/FCF- EPS past 5Y13.40% ROI-48.03% 52W High-25.74% Beta1.17
Dividend %- Quick Ratio17.17 Sales past 5Y-20.00% Gross Margin- 52W Low86.13% ATR0.26
Employees56 Current Ratio17.17 Sales Q/Q- Oper. Margin0.00% RSI (14)42.76 Volatility8.00% 7.30%
OptionableYes Debt/Eq0.14 EPS Q/Q86.95% Profit Margin- Rel Volume1.09 Prev Close3.44
ShortableNo LT Debt/Eq0.12 Earnings- Payout- Avg Volume59.47K Price3.49
Recom3.00 SMA20-6.66% SMA50-2.81% SMA2001.29% Volume29,527 Change1.51%
Date Action Analyst Rating Change Price Target Change
Aug-06-21Resumed Piper Sandler Overweight $30
Jan-06-21Initiated Stifel Buy $18
Sep-23-20Initiated Robert W. Baird Outperform $25
Jun-18-20Initiated Mizuho Buy $21
Apr-13-20Initiated H.C. Wainwright Buy $22
Mar-16-20Initiated BofA/Merrill Buy $18
Mar-12-20Initiated Canaccord Genuity Buy $20
Feb-18-20Initiated Guggenheim Buy $20
Jan-10-20Initiated Piper Sandler Overweight $20
Sep-22-23 08:00AM
Aug-17-23 09:02PM
Jul-27-23 09:34PM
Jul-18-23 06:30AM
May-09-23 03:28PM
10:42AM Loading…
Mar-10-23 10:42AM
Mar-09-23 10:41AM
Mar-08-23 05:00PM
Dec-12-22 01:00PM
Nov-16-22 10:39AM
Nov-15-22 10:30AM
Nov-14-22 04:03PM
Nov-03-22 09:05AM
Oct-01-22 08:53AM
04:02PM Loading…
Aug-09-22 04:02PM
Aug-03-22 08:00AM
Jul-27-22 08:00AM
Jul-04-22 06:42AM
May-16-22 08:00AM
May-09-22 04:05PM
May-05-22 08:00AM
Apr-24-22 08:38AM
Apr-13-22 10:00AM
Apr-07-22 08:00AM
Mar-15-22 08:00AM
Mar-08-22 04:01PM
Mar-01-22 04:03PM
Feb-22-22 08:00AM
Feb-03-22 08:00AM
09:15AM Loading…
Jan-24-22 09:15AM
Jan-10-22 08:00AM
Dec-11-21 05:30PM
Nov-12-21 07:05AM
Nov-09-21 08:00AM
Nov-04-21 04:05PM
Oct-25-21 12:57PM
Oct-01-21 09:08AM
Sep-29-21 08:00AM
Sep-27-21 11:55AM
Sep-09-21 08:00AM
Sep-07-21 08:00AM
Aug-05-21 04:05PM
Jun-08-21 01:56AM
May-26-21 08:00AM
May-17-21 10:29AM
May-12-21 08:00AM
May-05-21 08:00AM
May-04-21 08:00AM
May-03-21 08:00AM
Apr-26-21 10:19AM
Apr-17-21 09:20AM
Mar-26-21 08:00PM
Mar-25-21 04:00PM
Mar-18-21 08:00AM
Mar-02-21 08:00AM
Feb-05-21 08:00AM
Jan-28-21 11:15PM
Jan-25-21 11:56PM
Jan-23-21 11:45PM
Jan-20-21 11:53PM
Jan-14-21 11:25AM
Jan-08-21 12:49PM
Jan-07-21 08:00AM
Dec-10-20 08:00AM
Nov-23-20 08:00AM
Nov-18-20 01:59AM
Nov-11-20 08:00AM
Nov-10-20 08:00AM
Nov-09-20 08:00AM
Nov-05-20 02:00PM
Oct-20-20 08:00AM
Oct-14-20 05:05PM
Oct-13-20 03:06PM
Sep-23-20 09:33AM
Sep-15-20 01:11PM
Sep-10-20 08:00AM
Sep-09-20 08:00AM
Aug-20-20 01:26PM
Aug-19-20 12:00PM
Aug-12-20 04:01PM
Aug-06-20 08:00AM
Aug-05-20 08:00AM
Aug-03-20 10:50AM
Jul-15-20 07:21AM
Jul-07-20 07:35AM
Jul-03-20 12:00PM
Jul-02-20 12:54PM
Jul-01-20 04:01PM
Jun-24-20 10:24AM
Jun-22-20 09:05AM
Jun-19-20 12:49PM
Jun-15-20 08:00AM
Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAKER BROS. ADVISORS LPDirectorAug 17Buy0.69166,942115,6175,612,949Aug 17 05:08 PM
BAKER BROS. ADVISORS LPDirectorAug 16Buy0.68229,600156,2545,458,724Aug 17 05:08 PM
BAKER BROS. ADVISORS LPDirectorAug 15Buy0.631,888,8001,191,6165,246,614Aug 17 05:08 PM
Smith Sean MichaelInterim CFO, Prin Acct OffAug 11Sale0.621,32381821,637Aug 14 04:06 PM
Smith Sean MichaelInterim CFO, Prin Acct OffAug 10Option Exercise0.005,000022,960Aug 14 04:06 PM
Patel PritiFormer Chief Medical OfficerApr 03Sale0.693,7692,60837,313Apr 04 08:51 PM
Patel PritiFormer Chief Medical OfficerMar 31Option Exercise0.0010,000041,082Apr 04 08:51 PM
Patel PritiChief Medical OfficerFeb 02Sale0.6014,3808,58831,082Feb 03 04:32 PM
Smith Sean MichaelPrincipal Accounting OfficerFeb 02Sale0.603,3161,98015,960Feb 03 04:33 PM
Patel PritiChief Medical OfficerFeb 01Option Exercise0.0035,000045,462Feb 03 04:32 PM
Smith Sean MichaelPrincipal Accounting OfficerFeb 01Option Exercise0.0012,500019,276Feb 03 04:33 PM